Yang Xinyi, Zhu Yuqi, Xun Jingna, Liu Jun, Wen Qing, Lin Yixiao, Shen Xiaoting, Chen Jun, Yuan Songhua, Zhao Xiaying, Wang Jing, Pan Hanyu, Yang Jinlong, Liang Zhiming, Liang Yue, Lin Qinru, Liang Huitong, Zhou Chunyan, Jin Li, Xie Weijian, Liu Jianping, Lu Daru, Ying Tianlei, Shen Yinzhong, Zhang Xiaoyan, Xu Jianqing, Yin Chunhua, Wang Pengfei, Jiang Shibo, Lu Hongzhou, Zhu Huanzhang
State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
iScience. 2022 Sep 16;25(9):105016. doi: 10.1016/j.isci.2022.105016. Epub 2022 Aug 27.
The SARS-CoV-2 variants B.1.617.1 (Kappa) contain multiple mutations in the spike protein. However, the effect of B.1.617.1 lineage-related mutants on viral infectivity and inactivated-virus vaccine efficacy remains to be defined. We therefore constructed 12 B.1.617.1-related pseudoviruses and systematically studied the effects of mutations on virus infectivity and neutralization resistance to convalescent and inactivated virus vaccine sera. Our results show that the B.1.617.1 variant exhibited both higher infectivity and neutralization resistance in sera at 1 or 3 months after vaccination of 28 individuals and at 14 and 200 days after discharge of 15 convalescents. Notably, 89% of vaccines and 100% of the convalescent serum samples showed more than 2.5-fold reduction in neutralization against one single mutation: E484Q. Besides, we found a significant decrease in neutralizing activity in convalescent patients and BBIBP-CorV vaccines for B.1.1.529. These findings demonstrate that inactivated-virus vaccination or convalescent sera showed reduced, but still significant, neutralization against the B.1.617.1 variant.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变种B.1.617.1（卡帕）的刺突蛋白存在多个突变。然而，B.1.617.1谱系相关突变体对病毒感染性和灭活病毒疫苗效力的影响仍有待确定。因此，我们构建了12种与B.1.617.1相关的假病毒，并系统研究了这些突变对病毒感染性以及对康复期和灭活病毒疫苗血清的中和抗性的影响。我们的结果表明，在28名个体接种疫苗后1个月或3个月以及15名康复者出院后14天和200天时采集的血清中，B.1.617.1变种表现出更高的感染性和中和抗性。值得注意的是，89%的疫苗和100%的康复期血清样本对单个突变E484Q的中和作用降低了2.5倍以上。此外，我们发现康复期患者和BBIBP-CorV疫苗对B.1.1.529的中和活性显著降低。这些发现表明，灭活病毒疫苗接种或康复期血清对B.1.617.1变种的中和作用有所降低，但仍具有显著效果。
